IL-13, Human(CHO-expressed)
目录号 : GP29026本产品是在真核系统（CHO）中表达的重组人IL-13蛋白。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Interleukin 13 (IL-13) is an immunomodulatory cytokine produced primarily by activated Th2 cells, but also by mast cells and NK cells. IL-13 plays an important role in regulating Th2 cell development and can also enhance B cell proliferation and induce isotype switching, leading to increased IgE production. In addition, IL-13 exerts anti-inflammatory effects on monocytes and macrophages and inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6, and IL-8. Blocking IL-13 activity inhibits the pathophysiology of asthma. Human and mouse IL-13 exhibit cross-species reactivity.
This product is a recombinant human IL-13 protein expressed in a eukaryotic system. The protein is purified through proprietary chromatography technology. There is partial glycosylation modification. The protein size is 25~45 kDa as detected by SDS-PAGE.
白细胞介素13（IL-13）是一种免疫调节细胞因子，主要由活化的Th2细胞产生，也由肥大细胞和NK细胞产生。IL-13在调节Th2细胞发育方面起重要作用，也能够增强B细胞增殖并诱导同种型转换，导致Ig E产生增加。此外，IL-13对单核细胞和巨噬细胞发挥抗炎作用，并抑制炎性细胞因子如IL-1β、TNF-α、IL-6和IL-8的表达。阻断IL-13活性可抑制哮喘的病理生理学。人和小鼠IL-13具有跨物种反应性。
本产品是在真核系统中表达的重组人IL-13蛋白，通过专有色谱技术纯化蛋白，存在部分糖基化修饰，经SDS-PAGE检测蛋白大小为25~45 kDa。
| Purity | > 95% as analyzed by SDS-PAGE | Source | Human |
| Phycical Appearance | Shipping Condition | ||
| Synonyms | IL13; NC300 (Human); P600 (Murine) | ||
| Apparent Molecular Weight | 25~45 kDa, on SDS-PAGE under non-reducing conditions. | ||
| Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. | ||
| Biological Activity | ED50 < 15.0 ng/ml, measured in a cell proliferation assay using TF-1 cells, corresponding to a specific activity of > 6.7 × 105 units/mg. | ||
| Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. | ||
| Formulation | Lyophilized after extensive dialysis against PBS. | ||
Interleukin 13 (IL-13) is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1beta, TNF-alpha, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. Human and mouse IL-13 is cross-species reactive.
ED50 < 15.0 ng/ml, measured in a cell proliferation assay using TF-1 cells, corresponding to a specific activity of > 6.7 × 105 units/mg.
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.